Shares Outstanding Shares Outstanding n/a Close	14.8M
Shares Change (YoY) Shares Change (YoY) n/a Close	38.7%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	20.51%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	0%
Shares Floating Shares Floating n/a Close	14.11M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	5,918
FTD / Avg. Volume FTD / Avg. Volume n/a Close	14.92%

Short Selling Information

The latest short interest is 127.75K, so 0.86% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	127.75K
Short % of Shares Out Short % of Shares Out n/a Close	0.86%
Short % of Float Short % of Float n/a Close	0.87%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	5.86

Valuation Ratios

The PE ratio is -0.86 and the forward PE ratio is -5.33. Alterity Therapeutics's PEG ratio is 0.1.

PE Ratio PE Ratio n/a Close	-0.86
Forward PE Forward PE n/a Close	-5.33
PS Ratio PS Ratio n/a Close	4.09
Forward PS Forward PS n/a Close	17
PB Ratio PB Ratio n/a Close	1.19
P/FCF Ratio P/FCF Ratio n/a Close	-1.3
PEG Ratio PEG Ratio n/a Close	0.1

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Alterity Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.01.

Current Ratio Current Ratio n/a Close	3.54
Quick Ratio Quick Ratio n/a Close	3.54
Debt / Equity Debt / Equity n/a Close	0.01
Debt / EBITDA Debt / EBITDA n/a Close	-0.01
Debt / FCF Debt / FCF n/a Close	-0.01
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$401,928.5
Profits Per Employee Profits Per Employee n/a Close	$-1,912,346.4
Employee Count Employee Count n/a Close	10
Asset Turnover Asset Turnover n/a Close	0.21
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	46.09K
Effective Tax Rate Effective Tax Rate n/a Close	-0.24%

Stock Price Statistics

The stock price has increased by 138.71% in the last 52 weeks. The beta is 0.72, so Alterity Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.72
52-Week Price Change 52-Week Price Change n/a Close	138.71%
50-Day Moving Average 50-Day Moving Average n/a Close	3.9
200-Day Moving Average 200-Day Moving Average n/a Close	2.82
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	51.02
Average Volume (20 Days) Average Volume (20 Days) n/a Close	39,655

Income Statement

In the last 12 months, Alterity Therapeutics had revenue of 4.02M and earned -19.12M in profits. Earnings per share was -3.12.

Revenue Revenue n/a Close	4.02M
Gross Profit Gross Profit n/a Close	3.8M
Operating Income Operating Income n/a Close	-19.6M
Net Income Net Income n/a Close	-19.12M
EBITDA EBITDA n/a Close	-19.57M
EBIT EBIT n/a Close	-19.61M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-3.12

Full Income Statement

Balance Sheet

The company has 12.64M in cash and 159.04K in debt, giving a net cash position of 12.48M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	12.64M
Total Debt Total Debt n/a Close	159.04K
Net Cash Net Cash n/a Close	12.48M
Retained Earnings Retained Earnings n/a Close	-214.16M
Total Assets Total Assets n/a Close	10.55M
Working Capital Working Capital n/a Close	7.71M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.61M and capital expenditures -5.72K, giving a free cash flow of -12.61M.

Operating Cash Flow Operating Cash Flow n/a Close	-12.61M
Capital Expenditures Capital Expenditures n/a Close	-5.72K
Free Cash Flow Free Cash Flow n/a Close	-12.61M
FCF Per Share FCF Per Share n/a Close	0

Full Cash Flow Statement

Margins

Gross margin is 94.67%, with operating and profit margins of -487.69% and -475.79%.

Gross Margin Gross Margin n/a Close	94.67%
Operating Margin Operating Margin n/a Close	-487.69%
Pretax Margin Pretax Margin n/a Close	-474.65%
Profit Margin Profit Margin n/a Close	-475.79%
EBITDA Margin EBITDA Margin n/a Close	-486.94%
EBIT Margin EBIT Margin n/a Close	-487.69%
FCF Margin FCF Margin n/a Close	-313.78%

Dividends & Yields

ATHE does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for ATHE is $12, which is 170.3% higher than the current price. The consensus rating is "Strong Buy".

Price Target Price Target n/a Close	$12
Price Target Difference Price Target Difference n/a Close	170.3%
Analyst Consensus Analyst Consensus n/a Close	Strong Buy
Analyst Count Analyst Count n/a Close	1

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Jan 9, 2023. It was a backward split with a ratio of 1:10.

Last Split Date Last Split Date n/a Close	Jan 9, 2023
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:10

Scores

Altman Z-Score Altman Z-Score n/a Close	-23
Piotroski F-Score Piotroski F-Score n/a Close	2